Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561022 | 1.00 | FFAR1 (0.50) | FFAR1NAMPTDGAT1KLKB1L3MBTL1 | |
| SCHEMBL18991402 | 0.95 | FFAR1 (0.52) | FFAR1DGAT1KLKB1L3MBTL1CA1 | |
| Bicarbonate SCHEMBL18991577 | 0.93 | FFAR1 (0.50) | FFAR1DGAT1KLKB1L3MBTL1CA1 | |
| Bicarbonate SCHEMBL18991578 | 0.91 | FFAR1 (0.48) | FFAR1DGAT1KLKB1L3MBTL1CA1 | |
| SCHEMBL17785787 | 0.90 | FFAR1 (0.54) | FFAR1DGAT1KLKB1L3MBTL1CA1 | |
| SCHEMBL30875416 | 0.85 | FFAR1 (0.50) | FFAR1 | |
| SCHEMBL12435875 | 0.85 | FFAR1 (0.50) | FFAR1 | |
| SCHEMBL25248244 | 0.84 | FFAR1 (0.53) | FFAR1L3MBTL1 | |
| SCHEMBL29236822 | 0.83 | FFAR1 (0.54) | FFAR1L3MBTL1 | |
| SCHEMBL25258123 | 0.81 | FFAR1 (0.50) | FFAR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | FFAR1 2382/4885NAMPT 10/4885DGAT1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.